VIVIMED LABS LIMITED UNAUDITED CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER & HALF YEAR ENDED 30th SEP 2015

Rs in Lacs

| 1 Income From Operations (a) Net Soles / Income from C (b) Other Operating Income Total Income From Operatio a. Cost of Raw Materials Con. b. Purchase of Stock in Trade c. Changes in Inventories off in Changes in Inventories of Income b. Purchase of Stock in Trade c. Changes in Inventories of Income Costs J. Other Expenditure Total Expenses Profit / (Loss) from Operation France Costs Profit / (Loss) from Ordinary France Costs Profit / Loss from ordinary France Costs In Net Profit / Loss from ordinary France Costs In Net Profit / Loss from ordinary France Costs In Net Profit / Loss from ordinary France Costs In Net Profit / Loss from ordinary France Costs In Net Profit / Loss from ordinary France Costs In Net Profit / Loss from Operation In Reserve excluding Revaluation Parally Basic In Palad up Equity Share Capita (I France Costs) France Costs In Palad up Equity Share Capita (I France Costs) France Costs In Palad up Equity Share Capita (I France Costs) France Costs In Palad up Equity Share Capita (I France Costs) France Costs In Palad up Equity Share Capita (I France Costs) France Costs In Palad up Equity Share (Defore Expenses) France Costs | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | ++++ | | + | | - | | | No. | SI. | |
|--|---|--|--|---|---|---|--|---|--|--|---|---|--|---|--|---|--|---|---|---|---|---|---|--|---|--|---|---|---|--|--|--|-----------------------------------|----------------------|-----------|-----------|---|----------------|--|----------------------------|----------------|-----------------------------------|------------------------------------|--------------|-------------|---|------------|-------------|---------------------|---------------|-----------------|
| Total Expenses Profit / Loss / from Operations before Other Income, Finance Costs and exceptional Items (1 - 2) Other Income Other Income | from Operations before Other Income, Finance Costs and exceptional items [1 - 2] from Ordinary Activities before Finance Costs and exceptional items [3 - 4] from Ordinary Activities ofter Finance Costs but before exceptional items [5 - 6] from Ordinary activities ofter Finance Costs but before exceptional items [5 - 6] from ordinary activities after Tax [9 - 10] fixens [net of tax expenses Rs | itiure from Operations before Other Income, Finance Costs and exceptional Items [1 - 2] from Ordinary Activities before finance Costs and exceptional Items [3 - 4] from Ordinary Activities ofter Finance Costs but before exceptional items [3 - 6] ms om ordinary activities before Tax (7 - 8) ss. from ordinary activities after Tax (9 - 10) Items (net of tax expenses Rslacs) ss. from period (11 - 12) **(Loss) of associates st. st. st. st. st. st. st. | Itiure from Operations before Other Income, Finance Costs and exceptional items [1 - 2] from Ordinary Activities before Finance Costs and exceptional items [3 - 4] from Ordinary Activities ofter Finance Costs but before exceptional items [5 - 6] ms om ordinary activities ofter Finance Costs but before exceptional items [5 - 6] ms st from ordinary activities ofter Tax [7 - 8] st from ordinary activities ofter Tax [9 - 10] tems (net of tax expenses Rs | itiure from Operations before Other Income, Finance Costs and exceptional items [1 - 2] from Ordinary Activities before Finance Costs and exceptional items [3 - 4] from Ordinary Activities ofter Finance Costs but before exceptional items [5 - 6] ms om ordinary activities ofter Finance Costs but before exceptional items [5 - 6] ms from ordinary activities ofter Tax [9 - 10] Items [net of tax expenses Rs | itiure from Operations before Other Income, Finance Costs and exceptional items [1 - 2] from Ordinary Activities before finance Costs and exceptional items [3 - 4] from Ordinary Activities ofter Finance Costs but before exceptional items [3 - 6] ms om ordinary activities before Tax (7 - 8) ss from ordinary activities ofter Tax (9 - 10) tems (net of tax expenses Rslacs) ss from period (11 - 12) **(Loss) of associates st ofter taxes, Minority Interest and share of Profit / (Loss) of Associates (13 - 14 - 15) Share Capital (Face value of the Share shall be indicated) | Itiure from Operations before Other Income, Finance Costs and exceptional items [1 - 2] from Ordinary Activities before Finance Costs and exceptional items [3 - 4] from Ordinary Activities after Finance Costs but before exceptional items [5 - 6] ms from ordinary activities before Tax (7 - 8) from ordinary activities before Tax (7 - 8) ss from ordinary activities ofter Tax [9 - 10] ss from ordinary activities ofter Tax [9 - 10] ss from ordinary activities ofter Tax [9 - 10] ss from ordinary activities ofter Tax [9 - 10] ss from ordinary activities ofter Tax [9 - 10] ss from ordinary activities ofter Tax [9 - 10] ss from ordinary activities ofter Tax [9 - 10] ss from ordinary activities ofter Tax [9 - 10] ss from ordinary activities ofter Tax [9 - 10] ss from ordinary activities ofter Tax [9 - 10] ss from ordinary activities ofter Tax [9 - 10] ss from ordinary activities before Tax [9 - 10] ss from ordinary activities ofter Tax [9 - 10] ss from ordinary activities before Tax [9 - 10] | Itiure from Operations before Other Income, Finance Costs and exceptional items [1 - 2] from Ordinary Activities before Finance Costs and exceptional items [3 - 4] from Ordinary Activities after Finance Costs but before exceptional items [5 - 6] ms om ordinary activities after Finance Costs but before exceptional items [5 - 6] ms st from ordinary activities after Tax [7 - 10] Items (net of tax expenses Rslacs) st from ordinary activities after Tax [7 - 10] Items (net of tax expenses Rslacs) [loss) of associates st form ordinary activities after Tax [7 - 10] [loss) of associates st form ordinary activities after Tax [7 - 10] [loss) of associates st form ordinary activities after Tax [7 - 10] [loss] of associates st form ordinary activities after Tax [7 - 10] [loss] of associates [13 - 14 - 15] | Itiure from Operations before Other Income, Finance Costs and exceptional items [1 - 2] from Ordinary Activities before Finance Costs and exceptional items [3 - 4] from Ordinary Activities ofter Finance Costs but before exceptional items [5 - 6] ms om ordinary activities before Tax (7 - 8) soft portion ordinary activities after Tax [9 - 10] Items (net of tax expenses Rs | liture from Operations before Other Income, Finance Costs and exceptional Items [1 - 2] from Ordinary Activities before Finance Costs and exceptional Items [3 - 4] from Ordinary Activities ofter Finance Costs but before exceptional Items [5 - 6] from Ordinary activities before Tax (7 - 8) from ordinary activities before Tax (7 - 8) from ordinary activities ofter Tax (9 - 10) from from ordinary activities ofter Tax (9 - 10) from ordinary activities ofter Tax (9 - 10) | itiure from Operations before Other Income, Finance Costs and exceptional Items [1 - 2] from Ordinary Activities before Finance Costs and exceptional Items [3 - 4] from Ordinary Activities ofter Finance Costs but before exceptional Items [5 - 6] from Ordinary activities ofter Finance Costs but before exceptional Items [5 - 6] from ordinary activities before Tax [7 - 8] from ordinary activities before Tax [7 - 8] from ordinary activities ofter Tax [9 - 10] from ordinary activities ofter Tax [7 - 8] from ordinary activities ofter Tax [7 - 8] | Itiure from Operations before Other Income, Finance Costs and exceptional items [1 - 2] from Ordinary Activities before Finance Costs and exceptional items [3 - 4] from Ordinary Activities after Finance Costs but before exceptional items [5 - 6] ms om ordinary activities before Tax [7 - 8] om ordinary activities after Finance (3 - 10) Items (net of tax expenses Rs | Itiure from Operations before Other Income, Finance Costs and exceptional items [1 - 2] from Ordinary Activities before Finance Costs and exceptional items [3 - 4] from Ordinary Activities ofter Finance Costs but before exceptional items [5 - 6] ms om ordinary activities before Tax (7 - 8) ss from ordinary activities after Tax [9 - 10] tems (net of tax expenses Rslacs) ss for period (11 - 12) f (Loss) of associates | titure from Operations before Other Income, Finance Costs and exceptional items [1 - 2] from Ordinary Activities before Finance Costs and exceptional items [3 - 4] from Ordinary Activities ofter Finance Costs but before exceptional items [5 - 6] ms om ordinary activities before Tax [7 - 8] ss from ordinary activities after Tax [9 - 10] Items [net of tax expenses Rslacs] ss for period [11 - 12] ss for period [11 - 12] ss for period [11 - 12] | Hiure from Operations before Other Income, Finance Costs and exceptional Items [1 - 2] from Ordinary Activities before finance Costs and exceptional Items [3 - 4] from Ordinary Activities ofter Finance Costs but before exceptional items [3 - 6] ms om ordinary activities before Tax (7 - 8) ss. from ordinary activities after Tax (9 - 10) Items (net of tax expenses Rslacs) ss. from ordinary activities of tax expenses Rslacs) | Itiure from Operations before Other Income, Finance Costs and exceptional items [1 - 2] from Ordinary Activities before Finance Costs and exceptional items [3 - 4] from Ordinary Activities ofter Finance Costs but before exceptional items [5 - 6] from Ordinary activities ofter Finance Costs but before exceptional items [5 - 6] from ordinary activities before Tax [7 - 8] from ordinary activities ofter Tax [9 - 10] from Ordinary activities ofter Tax [9 - 10] from Operation [11 - 12] from Operation [11 - 12] from Operations before Other Income, Finance Costs and exceptional items [5 - 6] from Operations before Other Income, Finance Costs and exceptional items [3 - 4] | itiure from Operations before Other Income, Finance Costs and exceptional items [1 - 2] from Ordinary Activities before Finance Costs and exceptional items [3 - 4] from Ordinary Activities ofter Finance Costs but before exceptional items [5 - 6] ms om ordinary activities before Tax [7 - 8] ss from ordinary activities after Tax [9 - 10] Items [net of tax expenses RsLacs] stor period (11 - 12) Marsel of recombers | Itiure from Operations before Other Income, Finance Costs and exceptional items (1 - 2) from Ordinary Activities before Finance Costs and exceptional items (3 - 4) from Ordinary Activities ofter Finance Costs but before exceptional items (5 - 6) ms om ordinary activities before Tax (7 - 8) tems (net of tax expenses fis | Hiure from Operations before Other Income, Finance Costs and exceptional items [1 - 2] from Ordinary Activities before Finance Costs and exceptional items [3 - 4] from Ordinary Activities ofter Finance Costs but before exceptional items [5 - 6] ms om ordinary activities before Tax [7 - 8] ss from ordinary activities ofter Tax [9 - 10] tens (net of tax expenses its | itiure from Operations before Other Income, Finance Costs and exceptional Items [1 - 2] from Ordinary Activities before finance Costs and exceptional Items [3 - 4] from Ordinary Activities ofter Finance Costs but before exceptional Items [5 - 6] ms om ordinary activities before Tax [7 - 8] ss. from ordinary activities before Tax [9 - 10] tems (net of tax expenses 8s | Itiure from Operations before Other Income, Finance Costs and exceptional Items (1 - 2) from Ordinary Activities before Finance Costs and exceptional Items (3 - 4) from Ordinary Activities ofter Finance Costs but before exceptional Items (5 - 6) ms om ordinary activities before Tax (7 - 8) | itiure from Operations before Other Income, Finance Costs and exceptional items (1 - 2) from Ordinary Activities before Finance Costs and exceptional items (3 - 4) from Ordinary Activities ofter Finance Costs but before exceptional items (5 - 6) ms om ordinary activities before Tax (7 - 8) | liture from Operations before Other Income, Finance Costs and exceptional items (1 - 2) from Ordinary Activities before Finance Costs and exceptional items (3 - 4) from Ordinary Activities ofter Finance Costs but before exceptional items (5 - 6) from Ordinary activities before Tax (7 - 8) | Itiure from Operations before Other Income, Finance Costs and exceptional items [1 - 2] from Ordinary Activities before Finance Costs and exceptional items [3 - 4] from Ordinary Activities ofter Finance Costs but before exceptional items [5 - 6] from Ordinary activities before Tax [7 - 8] | Hiure From Operations before Other Income, Finance Costs and exceptional items (1 - 2) From Ordinary Activities before Finance Costs and exceptional items (3 - 4) From Ordinary Activities ofter Finance Costs but before exceptional items (5 - 6) From Ordinary Activities ofter Finance Costs but before exceptional items (5 - 6) | Iture from Operations before Other Income, Finance Costs and exceptional items [1 - 2] from Ordinary Activities before Finance Costs and exceptional items [3 - 4] from Ordinary Activities ofter Finance Costs but before exceptional items [5 - 6] | titure from Operations before Other Income, Finance Costs and exceptional items (1 - 2) from Ordinary Activities before Finance Costs and exceptional items (3 - 4) from Ordinary Activities ofter Finance Costs but before exceptional items (5 - 6) | Itture rom Operations before Other Income, Finance Costs and exceptional items (1 - 2) rom Ordinary Activities before Finance Costs and exceptional items (3 - 4) | titure rom Operations before Other Income, Finance Costs and exceptional Items (1 - 2) rom Ordinary Activities before finance Costs and exceptional Items (3 - 4) | Itture rom Operations before Other Income, Finance Costs and exceptional Items (1 - 2) rom Ordinary Activities before Finance Costs and exceptional Items (3 - 4) | Iture rom Operations before Other Income, Finance Costs and exceptional Items (1 - 2) | liture from Operations before Other Income, Finance Costs and exceptional items (1 - 2) | iture from Operations before Other Income, Finance Costs and exceptional items (1 - 2) | liture : | liture | liture | | e. Depreciation and Amortisation Expenses | nefit Expenses | c. Changes in inventiones of finished Goods, Work-in-Progress and Stock in Irade | | Stack in Trade | a. Cost of Raw Materials Consumed | Total Income From Operations (Net) | aring income | | (a) Net Sales / Income from Operations (Net of Excise Duty) | Operations | | rutucanis | Doughterstown | |
| 1,638.86 8,114.71 29,476.17 4,678.74 4,678.74 1,879.61 2,799.12 2,799.12 2,387.59 2,387.59 2,387.59 1,620.38 | 1,638,86 8,114.71 29,476.17 4,678.74 4,678.74 1,879.61 2,799.12 2,799.12 411.53 2,387.59 2,387.59 2,387.59 | 1,638,86 8,11471 29,476,17 4,678,74 4,678,74 1,879,61 2,799,12 2,799,12 2,387,59 2,387,59 2,387,59 | 1,638,86 8,11471 29,476.17 4,678.74 4,678.74 1,879.61 2,799.12 2,799.12 2,387.59 2,387.59 2,387.59 | 1,638,86 8,114.71 29,476.17 4,678.74 4,678.74 1,879.61 2,799.12 2,799.12 411.53 2,387.59 2,387.59 1,620.38 | 1,638.86 8,114.71 29,476.17 4,678.74 4,678.74 1,879.61 2,799.12 2,799.12 2,387.59 2,387.59 2,387.59 | 1,638,86 8,11471 29,476.17 4,678.74 4,678.74 1,879.61 2,799.12 2,799.12 2,387.59 2,387.59 2,387.59 | 1,638,86 8,114.71 29,476.17 4,678.74 4,678.74 4,678.74 2,799.12 2,799.12 2,799.59 2,387.59 2,387.59 2,387.59 | 1,638,86 8,114.71 29,476.17 4,678.74 4,678.74 1,879.61 2,799.12 2,799.12 411.53 2,387.59 2,387.59 | 1,638.86 8,114.71 29,476.17 4,678.74 4,678.74 4,678.74 1,879.61 2,799.12 2,799.12 2,387.59 2,387.59 | 1,638,86 8,11471 29,476,17 4,678,74 4,678,74 1,879,61 2,799,12 2,799,12 2,387,59 2,387,59 | 1,638,86 8,114,71 29,476,17 4,678,74 4,678,74 1,879,61 2,799,12 2,799,12 2,387,59 2,387,59 | 1,638,86 8,114.71 29,476.17 4,678.74 4,678.74 1,879.61 2,799.12 2,799.12 411.53 2,387.59 2,387.59 | 1,638,86 8,114.71 29,476.17 4,678.74 1,879.61 2,799.12 2,799.12 411.53 2,387.59 2,387.59 | 1,638.86 8,114.71 29,476.17 4,678.74 4,678.74 1,879.61 2,799.12 2,799.12 2,387.59 2,387.59 | 1,638,86 8,11471 29,476.17 4,678.74 4,678.74 1,879.61 2,799.12 2,799.12 2,387.59 2,387.59 | 1,638,86 8,11471 29,476,17 4,678,74 1,879,61 2,799,12 2,799,12 411.53 2,387.59 2,387.59 | 1,638,86 8,11471 29,476,17 4,678,74 4,678,74 1,879,61 2,799,12 2,799,12 2,387,59 2,387,59 | 1,638,86 8,114.71 29,476.17 4,678.74 4,678.74 1,879.61 2,799.12 2,799.12 411.53 2,387.59 | 1,638.86 8,114.71 29,476.17 4,678.74 4,678.74 1,879.61 2,799.12 2,799.12 2,799.12 2,387.59 | 1,638,86 8,114.71 29,476.17 4,678.74 4,678.74 1,879.61 2,799.12 2,799.12 411.53 2,387.59 | 1,638,86 8,11471 29,476,17 4,678,74 4,678,74 1,879,61 2,799,12 2,799,12 2,799,12 | 1,638,86 8,114.71 29,476.17 4,678.74 4,678.74 1,879.61 2,799.12 2,799.12 | 1,638.86 8,114.71 29,476.17 4,678.74 4,678.74 1,879.61 2,799.12 | 1,638,86 8,114,71 29,476,17 4,678,74 4,678,74 1,879,61 2,799,12 | 1,638.86 8,114.71 29,476.17 4,678.74 4,678.74 4,678.74 1,879.11 2,799.12 | 1,638.86 8,114.71 29,476.17 4,678.74 4,678.74 1,879.61 2,799.12 | 1,638.86 8,114.71 29,476.17 4,678.74 4,678.74 1,879.61 | 1,638.86 8,114.71 29,476.17 4,678.74 4,678.74 1,879.61 | 1,638.86 8,114.71 29,476.17 4,678.74 | 1,638.86 8,114.71 29,476.17 4,678.74 | 1,638.86 8,114.71 29,476.17 4,678.74 | 1,638.86 8,114.71 29,476.17 4,678.74 | 1,638.86 8,114.71 29,476.17 | 1,638.86 8,114.71 | 1,638.86 | 1,638.86 | | 3,776.21 | 497.50 | | | 15,448.89 | 34,154.91 | 452.10 | | 33.702.81 | | (Unaudited) | 30.09.2015 | | |
| 7,212.42 28,622.61 5,243.83 5,243.83 5,243.83 1,904.50 3,339.33 921.98 2,417.35 2,417.35 1,620.38 | 7,212.42 28,052.61 5,243.83 5,243.83 1,904.50 3,339.33 921.98 2,417.35 2,417.35 2,417.35 | 7,212.42 28,652.61 5,243.83 5,243.83 1,904.50 3,339.33 921.98 2,417.35 2,417.35 1,620.38 | 7,212.42 28,052.61 5,243.83 5,243.83 1,904.50 3,339.33 921.98 2,417.35 2,417.35 1,620.38 | 7,212.42 5,243.83 5,243.83 1,904.50 3,339.33 921.98 2,417.35 2,417.35 2,417.35 | 7,212.42 28,025.61 5,243.83 5,243.83 5,243.83 1,904.50 3,339.33 3,39.33 3,39.33 3,39.33 2,217.35 2,417.35 2,417.35 | 7,212.42 28,052.61 5,243.83 5,243.83 1,904.50 3,339.33 921.98 2,417.35 2,417.35 2,417.35 | 7,212.42 28,052.61 5,243.83 5,243.83 1,904.50 3,339.33 921.98 2,417.35 2,417.35 2,417.35 | 7,212.42 28,052.61 5,243.83 5,243.83 1,904.50 3,339.33 921.98 2,417.35 2,417.35 | 7,212.42 28,052.61 5,243.83 5,243.83 5,243.83 1,904.50 3,339.33 921.98 2,417.35 2,417.35 | 7,212.42 28,652.61 5,243.83 5,243.83 1,904.50 3,339.33 921.98 2,417.35 2,417.35 | 7,212.42 28,652.61 5,243.83 5,243.83 1,904.50 3,339.33 921.98 2,417.35 | 7,212.42 5,243.83 5,243.83 1,904.50 3,339.33 921.98 2,417.35 2,417.35 | 7,212.42 28,052.61 5,243.83 5,243.83 1,904.50 3,339.33 921.98 2,417.35 2,417.35 | 7,212.42 28,652.61 5,243.83 5,243.83 1,504.50 3,339.33 921.98 2,417.35 | 7,212.42 28,052.61 5,243.83 1,904.50 3,339.33 921.98 2,417.35 2,417.35 | 7,212.42 28,052.61 5,243.83 5,243.83 1,904.50 3,339.33 921.98 2,417.35 | 7,212.42 28,052.61 5,243.83 5,243.83 1,504.50 3,339.33 921.98 2,417.35 | 7,212.42 28,052.61 5,243.83 5,243.83 1,904.50 3,339.33 921.98 2,417.35 | 7,212.42 28,052.61 5,243.83 5,243.83 1,904.50 3,339.33 3,339.33 921.98 2,417.35 | 7,212.42 28,052.61 5,243.83 5,243.83 1,904.50 3,339.33 3,339.33 921.98 2,417.35 | 7,212.42 28,052.61 5,243.83 5,243.83 1,904.50 3,339.33 3,339.33 3,339.33 | 7,212.42 28,052.61 5,243.83 5,243.83 1,904.50 3,339.33 3,339.33 921.98 | 7,212.42 28,052.61 5,243.83 5,243.83 1,904.50 3,339.33 3,339.33 | 7,212.42 28,052.61 5,243.83 5,243.83 1,904.50 3,339.33 | 7,212.42 28,052.61 5,243.83 5,243.83 5,243.83 1,904.50 3,339.33 | 7,212.42 28,052.61 5,243.83 5,243.83 5,243.83 1,904.50 3,339.33 | 7,212.42 28,052.61 5,243.83 5,243.83 1,904.50 | 7,212.42 28,052.61 5,243.83 5,243.83 1,904.50 | 7,212.42 28,052.61 5,243.83 5,243.83 | 7,212.42 28,052.61 5,243.83 | 7,212.42 28,052.61 5,243.83 | 7,212.42 28,052.61 5,243.83 | 7,212.42 28,052.61 | 7,212.42 | 7 212 42 | | 1,478.38 | 4,543.03 | (553.92) | | | 15,372.70 | 33,296.44 | 143.60 | | 33.152.85 | | (Unaudited) | 30.06.2015 | | Ouarter Ended |
| 7,474,08 28,154,04 3,525,04 3,525,04 1,556,29 1,556,29 1,556,29 1,641,08 1,641,08 1,641,08 | 7,474,00 28,152,04 3,525,04 3,525,04 1,968,75 1,556,29 1,541,08 1,641,08 1,641,08 1,641,08 | 7,474,00 28,154,04 3,525,04 3,525,04 1,556,29 1,556,29 1,556,29 1,641,08 1,641,08 1,641,08 | 7,474,00 28,154,04 3,525,04 1,556,29 (84,79) 1,641,08 1,641,08 1,641,08 | 7,474,00 28,152,04 3,525,04 1,968,75 1,556,29 1,541,08 1,641,08 1,641,08 1,641,08 | 7,474,00 28,154,00 3,525,04 3,525,04 1,556,29 1,556,29 1,556,29 1,641,08 1,641,08 1,641,08 | 7,474,00 28,154,00 3,525,04 3,525,04 1,556,29 1,556,29 1,641,08 1,641,08 1,641,08 | 7,474,00 28,154,00 3,525,04 3,525,04 1,568,75 1,556,29 (84,79) 1,641,08 1,641,08 | 7,474,00 28,152,04 3,525,04 3,525,04 1,968,75 1,556,29 1,541,08 1,641,08 1,641,08 | 7,474,00 28,154,00 3,525,04 3,525,04 1,556,29 1,556,29 1,556,29 1,541,08 1,641,08 | 7,474,00 28,154,00 3,525,04 3,525,04 1,556,29 1,556,29 1,556,29 1,641,08 1,641,08 | 7,474,00 28,154,04 3,525,04 3,525,04 1,556,29 1,556,29 (84,79) 1,641,08 | 3,525,04 3,525,04 3,525,04 3,525,04 1,968.75 1,556.29 1,556.29 (84.79) 1,641.08 | 28,154,40 28,154,04 3,525,04 3,525,04 1,968,75 1,556,29 1,556,29 1,641,08 | 7,474,00 28,154,04 3,525,04 3,525,04 1,556,29 1,556,29 1,556,29 1,541,08 1,641,08 | 7,474,00 28,154,04 3,525,04 3,525,04 1,958,75 1,556,29 (84,79) 1,641,08 | 3,525,04 3,525,04 3,525,04 3,525,04 1,968.75 1,556.29 1,556.29 1,641.08 | 7,474,90 28,154,90 3,525,04 3,525,04 1,556,29 1,556,29 (84,79) 1,641,08 | 7,474,00 28,154,54 3,525,04 1,968,75 1,556,29 1,556,29 1,641,08 | 7,474,00 28,154,54 3,525,04 1,968,75 1,556,29 1,556,29 1,556,29 1,556,29 | 28,154,54 28,154,54 3,525,04 3,525,04 1,968,75 1,556,29 1,556,29 1,556,29 1,556,29 1,556,29 | 2,8154.54 3,525.04 3,525.04 1,968.75 1,556.29 1,556.29 1,556.29 | 7,474.00 28,154.54 3,525.04 3,525.04 1,968.75 1,556.29 1,556.29 (84.79) | 7,474.00 28,154.54 3,525.04 3,525.04 1,968.75 1,556.29 | 28,154,54 28,154,54 3,525,04 3,525,04 1,968,75 1,556,29 | 28,154.54 3,525.04 3,525.04 1,556.29 | 28,154.54 3,525.04 3,525.04 1,968.75 1,556.29 | 3,525.04 1,968.75 | 3,525.04 3,525.04 3,525.04 1,968.75 | 28,154.54 3,525.04 3,525.04 | 28,154.54 3,525.04 | 28,154.54 3,525.04 | 28,154.54 3,525.04 | 28,154.54 | 1,414.00 | | 2 474 60 | 1,653.82 | 4,225.10 | (1,917.53) | | | 16,718.48 | 31,679.58 | 315.71 | 00,000 | 31 363.86 | | (Unaudited) | 30.09.2014 | | |
| 57,528.79 9,922.56 9,922.56 3,784.12 6,138.44 1,333.51 4,804.94 1,620.38 1,620.38 | 57,528.79 9,922.56 9,922.56 3,784.12 6,138.44 6,138.44 1,333.51 4,804.94 4,804.94 4,804.94 1,620.38 | 57,528.79 9,922.56 9,922.56 3,784.12 6,138.44 1,333.51 4,804.94 4,804.94 1,620.38 | 57,528.79 9,922.56 9,922.56 3,784.12 6,138.44 1,333.51 4,804.94 4,804.94 4,804.94 1,620.38 | 57,528.79 9,922.56 9,922.56 3,784.12 6,138.44 6,138.44 1,333.51 4,804.94 4,804.94 4,804.94 1,620.38 | 57,528.79 9,922.56 9,922.56 3,784.12 6,138.44 1,333.51 4,804.94 4,804.94 1,620.38 | 57,528.79 9,922.56 9,922.56 3,784.12 6,138.44 1,333.51 4,804.94 4,804.94 1,620.38 | 57,528.79 9,922.56 9,922.56 3,784.12 6,138.44 1,333.51 4,804.94 4,804.94 4,804.94 4,804.94 | 57,528.79 9,922.56 9,922.56 3,784.12 6,138.44 6,138.44 1,333.51 4,804.94 4,804.94 | 57,528.79 9,922.56 9,922.56 3,784.12 6,138.44 1,333.51 4,804.94 4,804.94 | 57,528.79 9,922.56 9,922.56 3,784.12 6,138.44 1,333.51 4,804.94 4,804.94 | 57,528.79 9,922.56 9,922.56 3,784.12 6,138.44 1,333.51 4,804.94 4,804.94 | 57,528.79 9,922.56 9,922.56 3,784.12 6,138.44 6,138.44 1,333.51 4,804.94 4,804.94 | 57,528.79 9,922.56 9,922.56 3,784.12 6,138.44 1,333.51 4,804.94 | 57,528.79 9,922.56 9,922.56 3,784.12 6,138.44 1,333.51 4,804.94 4,804.94 | 57,528.79 9,922.56 9,922.56 3,784.12 6,138.44 6,138.44 1,333.51 4,804.94 4,804.94 | 57,528.79 9,922.56 9,922.56 3,784.12 6,138.44 1,333.51 4,804.94 4,804.94 | 57,528.79 9,922.56 9,922.56 3,784.12 6,138.44 1,333.51 4,804.94 4,804.94 | 57,528.79 9,922.56 9,922.56 3,784.12 6,138.44 6,138.44 1,333.51 4,804.94 | 57,528.79 9,922.56 9,922.56 9,922.56 3,784.12 6,138.44 1,333.51 4,804.94 | 57,528,79 9,922.56 9,922.56 9,922.56 3,784.12 6,138.44 1,333.51 4,804.94 | 57,528,79 9,922.56 9,922.56 3,784.12 6,138.44 1,333.51 | 57,528,79 9,922.56 9,922.56 3,784,12 6,138.44 1,333,51 | 57,528.79 9,922.56 9,922.56 3,784.12 6,138.44 6,138.44 | 57,528.79 9,922.56 9,922.56 9,922.56 3,784.12 6,138.44 | 57,528.79 9,922.56 9,922.56 9,922.56 3,784.12 6,138.44 | 57,528.79 9,922.56 9,922.56 9,922.56 3,784.12 6,138.44 | 57,528.79 9,922.56 9,922.56 3,784.12 | 57,528.79 9,922.56 9,922.56 3,784.12 | 57,528.79 9,922.56 9,922.56 | 57,528.79 9,922.56 | 57,528.79 9,922.56 | 57,528.79 9,922,56 | 57,528.79 | , | 10,021.10 | 15 227 13 | 3,117.24 | 8,319.24 | (56.42) | | - | 30,821.59 | 67,451.35 | 595.70 | 00,000,00 | 59 558 99 | | (Unaudited) | 30.09.2015 | , , , , , | Half Ye |
| 16,415,40 60,773.97 7,681.74 7,681.74 7,681.74 3,809.17 3,872.57 | 16,415.40 16,0773.97 7,681.74 7,681.74 3,809.17 3,872.57 3,872.57 518.45 3,354.12 3,354.12 3,354.12 1,570.38 | 16,415,40 60,773.97 7,681.74 7,681.74 7,681.74 3,809.17 3,872.57 518.45 3,354.12 3,354.12 3,354.12 3,354.12 | 16,415,40 60,773.97 7,681.74 7,681.74 3,809.17 3,872.57 518.45 3,354.12 3,354.12 3,354.12 | 16,415.40 60,773.97 7,681.74 7,681.74 7,681.74 3,809.17 3,872.57 3,872.57 518.45 3,354.12 3,354.12 3,354.12 | 16,415,40 60,773.97 7,681.74 7,681.74 7,681.74 3,872.57 3,872.57 3,872.57 518.45 3,354.12 3,354.12 1,620.38 | 16,415,40 60,773.97 7,681.74 7,681.74 7,681.74 3,809.17 3,872.57 3,872.57 518.45 3,354.12 3,354.12 3,354.12 | 16,415,40 60,773.97 7,681.74 7,681.74 7,681.74 3,809.17 3,872.57 518.45 3,354.12 3,354.12 3,354.12 | 16,415.40 60,773.97 7,681.74 7,681.74 7,681.74 3,809.17 3,872.57 3,872.57 518.45 3,354.12 3,354.12 | 16,415,40 60,773.97 7,681.74 7,681.74 7,681.74 3,809.17 3,872.57 3,872.57 3,872.57 3,872.57 3,872.57 3,872.57 3,872.57 3,872.57 3,872.57 3,872.57 3,872.57 3,872.57 3,872.57 3,872.57 3,872.57 3,872.57 3,872.57 | 16,415,40 60,773.97 7,681.74 7,681.74 7,681.74 3,809.17 3,872.57 518.45 3,354.12 3,354.12 | 16,415,40 60,773.97 7,681.74 7,681.74 3,809.17 3,872.57 518.45 3,354.12 | 16,415.40 60,773.97 7,681.74 7,681.74 7,681.74 3,809.17 3,872.57 3,872.57 518.45 3,354.12 3,354.12 | 16,415,40 60,773.97 7,681.74 7,681.74 3,809.17 3,872.57 3,872.57 518.45 3,354.12 | 16,415,40 60,773.97 7,681.74 7,681.74 3,699.17 3,872.57 3,872.57 518.45 3,354.12 3,354.12 | 16,415.40 60,773.97 7,681.74 7,681.74 3,809.17 3,872.57 518.45 3,354.12 | 16,415,40 60,773.97 7,681.74 7,681.74 3,691.77 3,872.57 3,872.57 518.45 3,354.12 | 16,415,40 60,773.97 7,681.74 7,681.74 7,681.74 3,809.17 3,872.57 518.45 3,354.12 | 16,415.40 60,773.97 7,681.74 7,681.74 3,809.17 3,872.57 518.45 3,354.12 | 16,415,40 60,773,97 7,681.74 7,681.74 7,681.74 3,809.17 3,872.57 3,872.57 3,872.57 3,872.57 3,872.57 | 16,415.40 60,773.97 7,681.74 7,681.74 3,809.17 3,872.57 518.45 3,354.12 | 16,415.40 60,773.97 7,681.74 7,681.74 3,809.17 3,872.57 3,872.57 | 16,415.40 60,773.97 7,681.74 7,681.74 3,809.17 3,872.57 518.45 | 16,415.40 60,773.97 7,681.74 7,681.74 3,809.17 3,872.57 | 16,415.40 60,773.97 7,681.74 7,681.74 3,809.17 3,872.57 | 16,415.40 60,773.97 7,681.74 7,681.74 3,809.17 3,872.57 | 16,415.40 60,773.97 7,681.74 7,681.74 7,681.74 3,809.17 3,872.57 | 16,415.40 60,773.97 7,681.74 7,681.74 3,809.17 | 16,415.40 60,773.97 7,681.74 7,681.74 3,809.17 | 16,415.40 60,773.97 7,681.74 7,681.74 | 16,415.40 60,773.97 7,681.74 | 16,415.40 60,773.97 7,681.74 | 16,415.40 60,773.97 7,681.74 | 16,415.40 | 16,415.40 | 16 115 10 | | 3,303.97 | 8,941.49 | (3,366.85) | | | 35,479.96 | 68,455.71 | 438.20 | 10,01,01 | 68 017 51 | | (Unaudited) | 30.09.2014 | | Half Year Ended |
| 1,22,939.08 15,657.41 15,657.41 7,903.68 7,753.73 548.69 7,205.04 7,205.04 1,620.38 | 1,22,93,00 15,657.41 15,657.41 7,903.68 7,753.73 548.69 7,205.04 7,205.04 7,205.04 1,620.38 | 1,22,939,08 15,657.41 15,657.41 7,903.68 7,753.73 548.69 7,205.04 7,205.04 7,205.04 1,620.38 | 1,22,939.08 15,657.41 15,657.41 7,903.68 7,753.73 7,753.73 548.69 7,205.04 7,205.04 7,205.04 7,205.04 7,205.04 | 1,22,939.08 15,657.41 15,657.41 7,903.68 7,753.73 7,753.73 548.69 7,205.04 7,205.04 7,205.04 | 1,22,939.08 15,657.41 15,657.41 7,903.68 7,753.73 548.69 7,205.04 7,205.04 7,205.04 7,205.04 | 1,22,939.08 15,657.41 15,657.41 7,903.68 7,753.73 7,753.73 548.69 7,205.04 7,205.04 7,205.04 | 1,22,939.08 15,657.41 15,657.41 7,903.68 7,753.73 7,753.73 548.69 7,205.04 7,205.04 7,205.04 | 1,22,939.08 15,657.41 15,657.41 7,903.68 7,753.73 7,753.73 548.69 7,205.04 7,205.04 | 1,22,939.08 15,657.41 15,657.41 7,903.68 7,753.73 7,753.73 548.69 7,205.04 7,205.04 | 1,22,939.08 15,657.41 15,657.41 7,903.68 7,753.73 548.69 7,205.04 7,205.04 | 1,22,939.08 15,657.41 15,657.41 7,903.68 7,753.73 7,753.73 548.69 7,205.04 7,205.04 | 1,22,939.08 15,657.41 15,657.41 7,903.68 7,753.73 7,753.73 548.69 7,205.04 7,205.04 | 1,22,939.08 15,657.41 15,657.41 7,903.68 7,753.73 7,753.73 548.69 7,205.04 7,205.04 | 1,22,939.08 15,657.41 15,657.41 7,903.68 7,753.73 7,753.73 548.69 7,205.04 7,205.04 | 1,22,939.08 15,657.41 15,657.41 7,903.68 7,753.73 7,753.73 7,253.73 7,205.04 7,205.04 | 1,22,939.08 15,657.41 15,657.41 7,903.88 7,753.73 7,753.73 548.69 7,205.04 7,205.04 | 1,22,939.08 15,657.41 15,657.41 7,903.68 7,753.73 548.69 7,205.04 7,205.04 | 1,22,939.08 15,657.41 15,657.41 7,903.68 7,753.73 7,753.73 548.69 7,205.04 | 1,2,939.08 15,657.41 15,657.41 7,903.68 7,753.73 7,753.73 548.69 7,205.04 | 1,22,939.08 15,657.41 15,657.41 7,903.68 7,753.73 7,753.73 7,753.73 548.69 7,205.04 | 1,2,939.08 15,657.41 15,657.41 7,903.68 7,753.73 7,753.73 | 1,22,939.08 15,657.41 15,657.41 7,903.68 7,753.73 7,753.73 | 1,22,939.08 15,657.41 15,657.41 7,903.68 7,753.73 7,753.73 | 1,22,939.08 15,657.41 15,657.41 15,657.41 7,903.68 7,753.73 | 1,22,939.08 15,657.41 15,657.41 7,903.68 7,753.73 | 1,22,939.08 15,657.41 15,657.41 15,657.41 7,903.68 7,753.73 | 1,22,939.08 15,657.41 15,657.41 7,903.68 | 1,22,939.08 15,657.41 15,657.41 7 903 68 | 1,22,939.08 15,657.41 15,657.41 | 1,22,939.08 | 1,22,939.08 | 1,22,939.08 | 1,22,939.08 | | 22,230.12 | 33 756 17 | 6,617,76 | 18,442.79 | (5,309.20) | | | 69.931.61 | 1,38,596.49 | 586.57 | 10.00,000,1 | 1 38 000 01 | | (Audied) | ended 31.03.2015 | Previous Year | |

- 10' th NOVEMBER '2015 The above Consolidated Unaudited Financial Results for the Quarter & Half year ended SEPTEMBER 30TH 2015 have been reviewed by Audit committee and taken on record by Board of Directors at their meeting held on
- subsidiaries, viz., (i) Creative Healthcare Private Limited, (ii) Vivimed Labs USA, Inc., (iii) Klar Sehen Private Limited, (iv) Octtantis Nobel Labs Private Limited, (v) Vivimed Labs (Alathur) put Limited (vi) Finaso Pharma put Limited and its stepdown subsidiary Vivimed Labs Europe Limited (ix) Vivimed Labs Mauritius Limited and its stepdown subsidaries (i) Vwimed Labs UK Limited, (ii) Vwimed Labs Spain, S.L. (iii) Union Quimico Formaceutica S.A.U., Spain, (iv) Holiday International Limited, UK & (v) Uquifa Mexico S.A. de C.V. Consolidated Financial Statements have been prepared in accordance with Accounting Standard-21 issued by ICAL. Consolidated Results are combined numbers of Vivimed tabs Limited and its direct wholly owned
- 3. The Company opted to publish only Consolidated Financial Results. Standalone results of the Company will be available on Company's webste www.vivimedlabs.com and also on BSE & NSE websites
- As per Accounting Standard 17 on Segment Reporting (AS-17), results of the two Segments "Specialty Chemicals" and "Pharma" are reported forresponding numbers of previous period I year have been reproved wherever personning.
- Corresponding numbers of previous period / year have been regrouped, wherever necessary
- The company has calculated depreciation as per the provisions under Companies Act of 2013

, 2) VIVIMED LABS LTD. has entered into a binding Agreement with CLARIANT INDIA LTD. to sell part of its Speciality Chemicals business. The Business Transfer Agreement (BTA) was entered between the pyo 29th Sep. 15. Under this BTA, the consideration receivable is Rs 380 Crs.

FOR VIVIMED (ABS DIVITED START VIVIMED ABS DIVINITED START VIVIMED (ABS DIVINITED START VIVIMED ABS DIVINITED ABS DIVIN

Place: Hyderabad Date: 10.11.2015

SEGMENT-WISE CONSOLIDATED FINANCIAL RESULTS AND CAPITAL EMPLOYED UNDER CLAUSE - 41 OF THE LISTING AGREEMENT VIVIMED LABS LIMITED

| | | | | | | Rs in Lacs |
|---|-------------|----------------|-------------|-----------------|-------------|-------------|
| | | 3 Months Ended | | Half Year Ended | Ended | FY 15 |
| Particulars | 30.09.2015 | 30.06.2015 | 30.09.2014 | 30.09.2015 | 30.09.2014 | 31-03-2015 |
| | (Unaudited) | (Unaudited) | (Unaudited) | (Unaudited) | (Unaudited) | (Audited) |
| 1. Segment Revenue | | | | | | |
| (net sales/income from each segment | | | | | | |
| should be disclosed under this head) | | | | | | |
| a.Speciality Chemicals Business | 9,430.16 | 9,575.42 | 9,866.70 | 19,005.58 | 18,728.36 | 44,620.88 |
| b.Pharma Business | 24,272.64 | 23,577.43 | 21,497.16 | 47,850.07 | 49,289.15 | 93,389.04 |
| Total | 33,702.81 | 33,152.85 | 31,363.86 | 66,855.65 | 68,017.51 | 1,38,009.92 |
| Less, Inter Segment Revenue | | | | ı | | |
| Net sales / Income from Operations | 33,702.81 | 33,152.85 | 31,363.86 | 66,855.65 | 68,017.51 | 1,38,009.92 |
| 2.Segment Results (Profit) (+) / Loss (-) | | | | | | |
| before tax and interest from each segment | | | | | | |
| a.Speciality Chemicals Business | 2,111.07 | 1,740.39 | 2,351.05 | 3,851.46 | 4,138.53 | 9,004.64 |
| b.Pharma Business | 2,567.67 | 3,503.44 | 1,173.99 | 6,071.10 | 3,543.21 | 6,652.77 |
| Total | 4,678.74 | 5,243.83 | 3,525.04 | 9,922.56 | 7,681.73 | 15,657.41 |
| Less: 1.Interest | 1,879.61 | 1,904.50 | 1,968.75 | 3,784.12 | 3,809.17 | 7,903.68 |
| 2.Other Un-allocable Expenditure | | | | | | |
| 3.Un-allocable Income | | | | | | |
| Total Profit Before Tax | 2,799.12 | 3,339.33 | 1,556.29 | 6,138.44 | 3,872.56 | 7,753.73 |
| 3. Capital Employed | | | | | | |
| a.Speciality Chemicals Business | 74,152.66 | 81,173.74 | 79,112.06 | 74,152.66 | 79,112.06 | 80,489.58 |
| b.Pharma Business | 66,437.84 | 68,788.00 | 64,002.71 | 66,437.84 | 64,002.71 | 68,208.23 |
| Total | 1,40,590.51 | 1,49,961.73 | 1,43,114.77 | 1,40,590.51 | 1,43,114.77 | 1,48,697.80 |
| | | | | | | |

Place: Hyderabad Date: 10.11.2015

(SANTOSH) XARALWAR) MANAGWG DIRECTOR & CEO FOR VIVIMED LABS LIMITED

VIVIMED LABS LIMITED

UNAUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER & HALF YEAR ENDED 30'th SEP'2015

| | | 19 | 17 | 16 | 15 | 14 | 13 | 12 | 11 | 10 | 9 | 00 | 7 | 9 | 6 | 4 | w | 2 | | Γ | | | | Γ | | | | 1-1 | | No. | SI. | Τ |
|-------------|-----------|---|---|----------|-------------------|--|----------|----|---|--------|----------|-------------------|---|---------------|---|--------------|--|----------------|----------------------|---|------------------------------|--|------------------------------|-----------------------------------|------------------------------------|----------------------------|---|------------------------|-------------|---------------------|-----------------|------------|
| (b) Diluted | (a) Basic | Earnings per Share (before Extraordinary Items) (of Rs/- each) (not annualised) | Paid up Equity Share Capital (Face value of the Share shall be indicated) | 1 | Minority Interest | Shore of Profit / (Loss) of associates | + | +- | Net Profit / Loss from ordinary activities after Tax (9-10) | ╁ | +- | Exceptional items | Profit / (Loss) from Ordinary Activities after Finance Costs but before exceptional items (5 - 6) | Finance Costs | Profit / (Loss) from Ordinary Activities before Finance Costs and exceptional items (3 - 4) | Other Income | Profit / (Loss) from Operations before Other Income, Finance Costs and exceptional items (1 - 2) | Total Expenses | f. Other Expenditure | e. Depreciation and Amortisation Expenses | d. Employee Benefit Expenses | c. Changes in Inventories of finished Inventories of Finished Goods, Work-in-Progress and Stock in Trade | b.Purchase of Stock in Trade | a. Cost of Raw Materials Consumed | Total Income From Operations (Net) | (b) Other Operating Income | (a) Net Sales / Income from Operations (Net of Excise Duty) | Income From Operations | | , Particulars | | |
| 1.40 | 1.40 | | 1,620.38 | 227.05 | | | 227.05 | , | 227.05 | 50.43 | 277.48 | | 277.48 | 1,502.14 | 1,779.62 | | 1,779.62 | 6,246.99 | 1,973.72 | 412.75 | 604.85 | 394.47 | | 2,861.20 | 8,026.61 | 17.48 | 8,009.12 | | (Unaudited) | 30.09.2015 | Q | |
| 1.34 | 1.34 | - | 1,620.38 | 216.80 | - | - | 216.80 | - | 216.80 | 64.86 | 281.66 | | 281.66 | 1,492.82 | 1,774.48 | | 1,774.48 | 6,209.53 | 1,752.94 | 484.51 | 529.77 | (12.89) | - | 3,455.20 | 7,984.01 | 12.70 | 7,971.31 | | (Unaudited) | 30.06.2015 | Quarter Ended | |
| 2.70 | 2.70 | - | 1620.38 | 437.33 | - | , | 437.33 | t | 437.33 | 136.30 | 573.63 | • | 573.63 | 1,491.92 | 2,065.55 | | 2,065.55 | 7,547.97 | 2,190.93 | 451.62 | 830.03 | (1,602.79) | | 5,678.17 | 9,613.52 | 40.34 | 9,573.18 | | (Unaudited) | 30.09.2014 | | |
| 2.74 | 2.74 | | 1,620.38 | 443.84 | | | 443.84 | | 443.84 | 115.29 | 559.13 | | 559.13 | 2,994.96 | 3,554.10 | | 3,554.10 | 12,456.52 | 3,726.66 | 897.26 | 1,134.62 | 381.58 | - | | 16,0 | | 15,980.44 | | (Unaudited) | 30.09.2015 | Half Ye | |
| 5.68 | 5.68 | | 1,620.38 | 920.45 | | | 920.45 | | | | 1,233.93 | | 1,233.93 | 2,919.52 | 4,153.45 | | 4,153.45 | 15,731.01 | 4,371.19 | 899.78 | | (3,469.46) | , | 12,549.88 | 19,884.46 | 38.44 | 19,846.02 | , | (Unaudited) | 30.09.2014 | Half Year Ended | |
| 11.69 | 11.69 | | 1,620.38 | 1,893.52 | | | 1,893.52 | | 1,893.52 | 531.99 | 2,425.51 | | 2,425.51 | 6,233.53 | 8,659.04 | | 8,659.04 | 34,499.17 | 1 | | 2,788.34 | (5,319.45) | | 25,110.30 | 43,158.21 | 143.40 | 43,014.81 | | (Audied) | ended 31.03.2015 | Previous Year | Rs in Lacs |

^{1.} The above Standalone Unaudited Financial Results for the Quarter & Half year ended SEPTEMBER'30'TH 2015 have been reviewed by Audit committee and taken on record by Board of Directors at their meeting held on 10' th NOVEMBER '2015

As per Accounting Standard 17 on Segment Reporting (AS-17), results of the two Segments "Specialty Chemicals" and "Pharma" are reported.

(a) VIVIMED LABS LTD. has entered into a binding Agreement with CLARIANT INDIA LTD. to sell part of its Speciality Chemicals business. The Business Transfer Agreement (BDA) was entered Sep. 115. Under this BTA, the consideration receivable is Rs 380 Crs.

Place: Hyderabad Date: 10.11.2015

(SANTOSH WARDALWAR)
MANAGING DIRECTOR & CEO

npanies on 29 th

^{2.} The Company opted to publish anly Consolidated Financial Results. Standalane results of the Company will be available on Company's website www.vivimedlabs.com and also on BSE & NSE websites.

^{4.} Corresponding numbers of previous period / year have been rearranged, wherever peressary

[.] Corresponding numbers of previous period / year have been regrouped, wherever necessary.

[.] The company has calculated depreciation as per the provisions under Companies Act of 2013.

VIVIMED LABS LIMITED

SEGMENT-WISE STANDALONE FINANCIAL RESULTS AND CAPITAL EMPLOYED UNDER CLAUSE - 41 OF THE LISTING AGREEMENT

| | X |
|---|-----|
| ļ | S |
| ı | 3 |
| ı | La |
| ı | ನ್ನ |

| | \ | | | | | |
|--------------|-------------|-----------------|-------------|----------------|-------------|---|
| 1,13,924.55 | 1,05,403.26 | 1,11,417.99 | 1,05,403.27 | 1,13,924.55 | 1,11,417.99 | Total |
| 31,968.95 | 29,108.61 | 32,244.29 | 29,108.61 | 31,968.95 | 32,244.29 | b.Pharma Business |
| 81,955.60 | 76,294.65 | 79,173.69 | 76,294.65 | 81,955.60 | 79,173.69 | a.Speciality Chemicals Business |
| | | | | | | 3. Capital Employed |
| 2,425.51 | 1,233.92 | 559.13 | 573.63 | 281.66 | 277.48 | Total Profit Before Tax |
| | | | | | | 3.Un-allocable Income |
| | | | | 1 | | 2.Other Un-allocable Expenditure |
| 6,233.53 | 2,919.52 | 2,994.96 | 1,491.92 | 1,492.82 | 1,502.14 | Less: 1.Interest |
| 8,659.04 | 4,153.45 | 3,554.10 | 2,065.55 | 1,774.47 | 1,779.62 | Total |
| 1,387.72 | 856.36 | 333.64 | 328.87 | 137.57 | 196.07 | b.Pharma Business |
| 7,271.32 | 3,297.08 | 3,220.45 | 1,736.68 | 1,636.90 | 1,583.55 | a.Speciality Chemicals Business |
| | | | | | | before tax and interest from each segment |
| | | | | | | 2.Segment Results (Profit) (+) / Loss (-) |
| 43,014.81 | 19,846.02 | 15,980.44 | 9,573.18 | 7,971.31 | 8,009.12 | Net sales / Income from Operations |
| | | | | - | | Less, Inter Segment Revenue |
| 43,014.81 | 19,846.02 | 15,980.44 | 9,573.18 | 7,971.31 | 8,009.12 | Total |
| 8,073.66 | 3,931.99 | 3,999.72 | 1,658.84 | 1,905.28 | 2,094.44 | b.Pharma Business |
| 34,941.15 | 15,914.03 | 11,980.72 | 7,914.34 | 6,066.04 | 5,914.68 | a.Speciality Chemicals Business |
| | | | | | | should be disclosed under this head) |
| | | | | | | (net sales/income from each segment |
| | | | | | | 1. Segment Revenue |
| (Audited) | (Unaudited) | (Unaudited) | (Unaudited) | (Unaudited) | (Unaudited) | |
| 31-03-2015 | 30.09.2014 | 30.09.2015 | 30.09.2014 | 30.06.2015 | 30.09.2015 | Particulars |
| FY 15 | r Ended | Half Year Ended | | 3 Months Ended | | |
| INS III Laus | | | | | | |

Date: 10.11.2015 Place : Hyderabad

MANAGING DIRECTOR & CEO

(SANTOŠK VARALWAR)

FOR VIVIMED LABS LIMITED

VIVIMED LABS LIMITED UNAUDITED STANDALONE & CONSOLIDATED BALANCE SHEET AS AT SEPTEMBER'30th,2015

Rs in Lakhs


| | | STANDA | ALONE | CONSOL | IDATED |
|------|---|-------------|---|-------------|---|
| | | As at | As at | As at | As at |
| S.No | Particulars | 30.09.2015 | 31.03.2015 | 30.09.2015 | 31.03.2015 |
| | | (Unaudited) | (Audited) | (Unaudited) | (Audited) |
| (A) | EQUITY AND LIABILITIES | | (************************************** | (0 | (,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,, |
| 1 | Shareholders funds | | | | |
| | (a) Share Capital | | | | |
| | | | | | |
| | i) Equity Share Capital | 1,620.38 | 1,620.38 | 1,620.38 | 1,620.38 |
| | ii) Preference Share capital | - | | 6,394.56 | 6,394.56 |
| | (b) Reserves and Surplus | 35,004.62 | 35,774.58 | 49,278.59 | 47,908.55 |
| | (c) Money Received against Share Warrants | - | | | |
| | Sub Total Shareholders Funds | 36,625.00 | 37,394.96 | 57,293.53 | 55,923.49 |
| 2 | Non-current liabilities | | | | |
| | a) Long-term borrowings | 23,407.02 | 30,780.73 | 33,079.30 | 48,338.15 |
| | (b) Deferred tax liabilities (net) | 3,154.78 | 3,154.78 | 1,019.04 | 937.13 |
| | (c) Other long-term liabilities | 13,310.20 | 12,282.80 | 3,525.36 | 4,243.81 |
| | (d) Long-term provisions | 295.82 | 301.05 | 314.72 | 316.96 |
| | Sub-total - Non-current liabilities | 40,167.82 | 46,519.36 | 37,938.43 | 53,836.05 |
| 3 | Current liabilities | | | | |
| | (a) Short-term borrowings | 34,625.17 | 29,118.86 | 45,358.55 | 38,938.26 |
| | (b) Trade payables | 1,920.36 | 4,560.86 | 18,024.38 | 18,871.38 |
| | (c) Other current liabilities | 16,116.96 | 10,166.27 | 31,971.15 | 17,637.68 |
| | (d) Short-term provisions | 3,671.05 | 2,515.40 | 6,177.17 | 4,638.95 |
| | Sub-total - Current liabilities | 56,333.54 | 46,361.39 | 1,01,531.24 | 80,086.27 |
| | TOTAL - EQUITY AND LIABILITIES | 1,33,126.36 | 1,30,275.71 | 1,96,763.21 | 1,89,845.81 |
| (B) | ASSETS | | | | |
| 1 | Non-current assets | | | | |
| | (a) Fixed assets | | | | |
| | (i) Tangible Assets | 35,648.71 | 36,466.11 | 69,254.45 | 69,629.81 |
| | (ii) Intangible Assets | 1,129.71 | 1,189.17 | 10,127.58 | 11,717.24 |
| | (iii) Capital work in progress | 6,827.92 | 6,327.21 | 9,448.90 | 9,028.16 |
| | (b) Non Current Investment | - | 23,004.55 | 270.00 | 270.00 |
| | (c) Long Term Loans and advances | 23,004.55 | | | |
| | (d) Other Non Current Assets | - | - | 4.29 | 4.37 |
| 2 | Sub-total - Non-current assets | 66,610.90 | 66,987.04 | 89,105.22 | 90,649.59 |
| 2 | Current Assets | 07.57.45 | | | |
| | (a) Inventories | 27,577.45 | 22,249.87 | 50,758.32 | 43,143.27 |
| | (b) Trade receivables (c) Cash and cash equivalents | 19,997.47 | 22,807.52 | 27,346.30 | 32,957.80 |
| | (d) Short-term loans and advances | 805.08 | 1,399.45 | 2,344.16 | 2,667.07 |
| | (e) Other current assets | 17,542.32 | 16,238.69 | 26,248.58 | 18,521.29 |
| | Sub-total - Current assets | 593.14 | 593.14 | 960.62 | 1,906.78 |
| | TOTAL - ASSETS | 66,515.46 | 63,288.67 | 1,07,657.99 | 99,196.21 |
| | IOIAL - MOSETO | 1,33,126.36 | 1,30,275.71 | 1,96,763.21 | 1,89,845.81 |
| | | | | | |




| | Pai | rt II | | | | | | |
|-------|---|----------|--------------------------------|--------------------------------|--------------------------------|----------------------------------|----------------------------------|-----------------------|
| | | | Select | Information for | the Quarter and | Half Year Ended | 30/09/2015 | |
| SL.No | Particulars | | Quarter ended 30/09/2015 | Quarter ended 30/06/2015 | Quarter ended 30/09/2014 | Half Year ended 30/09/2015 | Half Year ended 30/09/2014 | Year ended 31/03/2015 |
| A | PARTICULARS OF SHAREHOLDING | | | | | | | |
| | Public Shareholdin | g | | | | | 10000050 | |
| | Number of Shares | | 10210555 | 10210555 | 10026058 | 10210555 | 10026058 | 10059058 |
| | Percentage of Shareholding | | 63.01% | 63.01% | 61.87% | 63.01% | 61.87% | 62.08% |
| | Promoter and Pror Group Shareholdin | g | | | | | | |
| | (a)Pledged/ Encum | bered | | | | | | |
| | Number of Shares | | 5248116 | 4998000 | 3110455 | 5248116 | 3110455 | 4823000 |
| | Percentage of share % of the total shareholding of pro and promoter grou | omoter | 87.57% | 83.39% | 50.35% | 87.57% | 50.35% | 78.49% |
| | Percentage of share % of the total share of the company) | es (as a | 32.39% | 30.85% | 19.20% | 32.39% | 19.20% | 29.76% |
| | (b) Non-encumber | ed | | | | | | |
| ! | Number of Shares | | 745112 | 995228 | 3067270 | 745112 | 3067270 | 1321725 |
| | Percentage of shar % of the total shareholding of pro and promoter grou | omoter | 12.43% | 16.61% | 49.65% | 12.43% | 49.65% | 21.51% |
| | Percentage of share % of the total share of the company) | es (as a | 4.60% | 6.14% | 18.93% | 4.60% | 18.93% | 8.16% |

Investor's Complaints

| Sl.no | Particulars | 3 months ended 30/09/2015 |
|-------|--|---------------------------|
| В | Pending at the beginning of the quarter | Nil |
| | Received during the quarter | Nil |
| | Disposed of during the quarter | Nil |
| | Remaining unresolved at the end of the quarter | Nil |





Tel.

: (91-40) 2332 6666, 2331 2554

2339 3967, 2332 1470

Fax E-mail : (91-40) 2339 2474 : pmurali.co@gmail.com

info@pmurali.com

Website: www.pmurali.com

To
The Board of Directors
VIVIMED LABS LIMITED
Hyderabad

Limited Review Report for the quarter ended 30th September, 2015

- 1. We have reviewed the accompanying statement of unaudited financial results of M/s. VIVIMED LABS LIMITED for the quarter ended 30th September, 2015 except for the disclosures regarding 'Public Shareholding' and 'Promoter and Promoter Group Shareholding' which have been traced from disclosures made by the management and have not been audited by us. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors/ committee of Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.
- 2. We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, Review of interim financial information performed by the independent auditor of the entity issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
- 3. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Clause 41 of the Listing Agreement including the manner in which it is to be disclosed, or that it contains any material misstatement.

For P. Murali & Co. artered Accountants

Partner

Place: Hyderabad

Date: 10th November 2015